Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma

International Journal of Oncology

Volumn 44, Issue 1, 2014, Pages 99-104

  Dambrauskas, Zilvinas ^a   Svensson, Helena ^b   Joshi, Meghnad ^b,c   Hyltander, Anders ^b   Naredi, Peter ^b   Iresjö, Britt Marie ^b  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Stem Plus Biotech   (India)

Author keywords

Cancer differentiation; MICA B; Pancreatic cancer

Indexed keywords

ACUTE PHASE PROTEIN; GLYCOSYLATED PROTEIN; HEAT SHOCK PROTEIN; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I RELATED CHAIN A; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I RELATED CHAIN B; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 84891919607     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2156     Document Type: Article

References (36)

1. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H and Buchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91: 586-594, 2004.
2. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C and Neoptolemos JP: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82: 111-115, 1995.
3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
4. McCracken M, Olsen M, Chen MS Jr, et al: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 57: 190-205, 2007.
5. Buchler MW, Wagner M, Schmied BM, Uhl W, Friess H and Z'Graggen K: Changes in morbidity after pancreatic resection: toward the end of completion pancreatectomy. Arch Surg 138: 1310-1315, 2003.
6. Diener MK, Heukaufer C, Schwarzer G, et al: Pancreatico-duodenectomy (classic Whipple) versus pylorus-preserving pancreaticoduodenectomy (pp Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database Syst Re 16: CD006053, 2008.
7. Jaffee EM, Hruban RH, Biedrzycki B, et al: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19: 145-156, 2001.
8. Picozzi VJ, Kozarek RA and Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185: 476-480, 2003.
9. Dranoff G: Coordinated tumor immunity. J Clin Invest 111: 1116-1118, 2003.
10. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH and Spies T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96: 6879-6884, 1999.
11. Groh V, Wu J, Yee C and Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738, 2002.
12. Pende D, Rivera P, Marcenaro S, et al: Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62: 6178-6186, 2002.
13. Liu G, Atteridge CL, Wang X, Lundgren AD and Wu JD: The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol 184: 3346-3350, 2010.
14. Salih HR, Rammensee HG and Steinle A: Cutting edge: downregulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-4102, 2002.
15. Waldhauer I, Goehlsdorf D, Gieseke F, et al: Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68: 6368-6376, 2008.
16. Doubrovina ES, Doubrovin MM, Vider E, et al: Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 171: 6891-6899, 2003.
17. Xu X, Rao G, Gaffud MJ, et al: Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer. J Clin Endocrinol Metab 91: 2704 -2712, 2006.
18. Xu X, Rao GS, Groh V, et al: Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer 11: 194, 2011.
19. Duan X, Deng L, Chen X, et al: Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 28: 466-474, 2011.
20. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M and Spies T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93: 12445-12450, 1996.
21. Bauer S, Groh V, Wu J, et al: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729, 1999.
22. Diefenbach A, Jensen ER, Jamieson AM and Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413: 165-171, 2001.
23. Hayakawa Y, Kelly JM, Westwood JA, et al: Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 169: 5377-5381, 2002.
24. Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3: 781-790, 2003.
25. Watson NF, Spendlove I, Madjd Z, et al: Expression of the stressrelated MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int J Cancer 118: 1445-1452, 2006.
26. Marten A, von Lilienfeld-Toal M, Buchler MW and Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 119: 2359-2365, 2006.
27. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A and Salih HR: Soluble MICA in malignant diseases. Int J Cancer 118: 684-687, 2006.
28. Chung HW and Lim JB: Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma. Cancer Sci 102: 1673-1679, 2011.
29. Bahram S: MIC genes: from genetics to biology. Adv Immunol 76: 1-60, 2000.
30. Collins RW, Stephens HA, Clare MA and Vaughan RW: High resolution molecular phototyping of MICA and MICB alleles using sequence specific primers. Hum Immunol 63: 783-794, 2002.
31. Stephens HA: MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol 22: 378-385, 2001.
32. Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, et al: Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 8: 16, 2008.
33. Chitadze G, Lettau M, Bhat J, et al: Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the 'a disintegrin and metalloproteases' 10 and 17. Int J Cancer 133: 1557-1566, 2013.
34. Ashiru O, Boutet P, Fernandez-Messina L, et al: Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 70: 481-489, 2010.
35. Collins RW: Human MHC class I chain related (MIC) genes: their biological function and relevance to disease and transplantation. Eur J Immunogenet 31: 105-114, 2004.
36. Bedel R, Thiery-Vuillemin A, Grandclement C, et al: Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells. Cancer Res 71: 1615-1626, 2011.